467 510

Cited 0 times in

비소세포폐암의 새로운 표적치료

Other Titles
 New targeted therapies for non-small cell lung cancer 
Authors
 이은혜  ;  곽세현  ;  김치영  ;  권혜란  ;  김은영  ;  장윤수 
Citation
 JOURNAL OF THE KOREAN MEDICAL ASSOCIATION(대한의사협회지), Vol.66(3) : 180-190, 2023-03 
Journal Title
JOURNAL OF THE KOREAN MEDICAL ASSOCIATION(대한의사협회지)
ISSN
 1975-8456 
Issue Date
2023-03
Keywords
Lung neoplasms ; Non-small-cell lung carcinoma ; Therapeutics ; Molecular targeted therapy
Abstract
Background: Lung cancer is representative of a high frequency and high mortality disease and ranks at the top in incidence and mortality in Korea, when excluding thyroid cancer. In this manuscript, we focused on current targeted therapies for lung cancer used widely in the medical field.

Current Concepts: The majority of patients with lung cancer cannot be treated with surgery only and require chemotherapeutics or radiation therapy. Currently, classical chemotherapeutic agents, targeted agents, and immune checkpoint inhibitors are the most widely used. Recently, the Research and Development of antibody drug conjugates is gaining attention, and this may become a more widely prescribed treatment in the future.

Among the available treatment options, targeted therapy is becoming increasingly feasible and widespread for treating inoperable lung cancers, where driver mutations have been identified, and for adjuvant or neoadjuvant therapies. Next-generation sequencing (NGS) improves the ability to identify driver mutations that were previously difficult to detect and can also be performed on blood samples where no cancer tissue is available for testing.

This makes it possible to identify therapeutic targets for targeted therapy more rapidly.

Discussion and Conclusion: The most common type of lung cancer in Korea is adenocarcinoma, for which a driver mutation has been identified. Newly developed drugs target previously problematic mutations or cancer cell lines that have acquired resistance induced during the treatment process. The survival rate of patients with lung cancer is expected to improve with the development of tailored treatments for targets identified from the NGS data of the patient. This paper will help clinicians understand the current state of targeted therapies for lung cancer treatment.
Files in This Item:
T202302529.pdf Download
DOI
10.5124/jkma.2023.66.3.180
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
Yonsei Authors
Kwak, Se Hyun(곽세현)
Gwon, Hye Ran(권혜란)
Kim, Eun Young(김은영) ORCID logo https://orcid.org/0000-0002-3281-5744
Kim, Chi Young(김치영)
Lee, Eun Hye(이은혜) ORCID logo https://orcid.org/0000-0003-2570-3442
Chang, Yoon Soo(장윤수) ORCID logo https://orcid.org/0000-0003-3340-4223
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/194176
사서에게 알리기
  feedback

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse

Links